HS-173 as a novel inducer of RIP3-dependent necroptosis in lung cancer

Area of Science:

• Oncology
• Cell Biology
• Pharmacology

Background:

• Necroptosis, a regulated form of necrotic cell death, is mediated by receptor-interacting kinase 3 (RIP3).
• Necroptosis is emerging as a promising therapeutic strategy for targeting cancer cells.
• Identifying novel agents that induce necroptosis is crucial for cancer therapy development.

Purpose of the Study:

• To identify and characterize a novel chemotherapeutic agent, HS-173, that induces RIP3-mediated necroptosis in lung cancer.
• To elucidate the molecular mechanisms by which HS-173 triggers necroptosis.
• To evaluate the efficacy of HS-173 in inhibiting tumor growth in vivo.

Main Methods:

• Screening of chemotherapeutics for necroptosis-inducing activity.
• Assessment of cell viability and cell death in lung cancer cell lines with and without RIP3 expression.
• Inhibition studies using necrostatin-1 and dabrafenib.
• Western blot analysis to detect RIP3 and MLKL phosphorylation.
• Analysis of necroptotic markers (HMGB1) and morphological changes.
• Evaluation of tumor growth in mouse xenograft models.

Main Results:

• HS-173 significantly decreased cell survival in RIP3-expressing lung cancer cells in a dose-dependent manner.
• HS-173-induced cell death was reversed by necroptosis inhibitors, confirming the mechanism.
• HS-173 treatment led to increased phosphorylation of RIP3 and MLKL, activating the RIP3/MLKL signaling pathway.
• Elevated levels of HMGB1 and characteristic necroptotic morphology were observed.
• HS-173 effectively inhibited tumor growth in mouse xenograft models through necroptosis stimulation.

Conclusions:

• HS-173 is a potent inducer of RIP3-mediated necroptosis in lung cancer cells.
• The drug activates the RIP3/MLKL signaling pathway, leading to programmed cell death.
• HS-173 demonstrates therapeutic potential for lung cancer treatment by inhibiting tumor growth via necroptosis.